Annovis Wins Patent Protection for Buntanetap Form B Through 2044

November 12, 2026
Annovis Wins Patent Protection for Buntanetap Form B Through 2044
  • Annovis Bio announced that U.S. Patent No. 12,780,831, granted November 3, 2026, covers buntanetap D-tartrate Form B, a crystalline form used in the company’s clinical program, with protection through June 21, 2044.

  • The patent’s 11 claims cover Form B’s crystalline structure, high-purity form and preparation from Form A; Annovis describes Form B as a stable, highly crystalline dihydrate distinct from Form A, a semi-crystalline anhydrate.

  • The patent arrives as Annovis has completed enrollment in its Phase 3 trial of once-daily 30 mg buntanetap in people with early Alzheimer’s disease who test positive for plasma pTau217; the study assesses symptomatic effects at six months and disease-modifying effects at 18 months.

  • Form B is being used in the Phase 3 Alzheimer’s trial and an open-label Parkinson’s study, and comparisons in mice, dogs and humans found drug-exposure profiles similar to Form A in plasma, brain and cerebrospinal fluid; Annovis said the findings were submitted to the FDA and published in a peer-reviewed paper.

  • The FDA cleared the transition to Form B for future clinical trials in July 2024 after reviewing bridging studies and manufacturing data.

  • Annovis expects top-line results from the six-month symptomatic analysis in the first quarter of 2027 and from the 18-month disease-modifying analysis in the first quarter of 2028, and says it has begun preparing New Drug Application submissions to follow each readout.

Summary based on 3 sources


Get a daily email with more Longevity stories

More Stories